Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 18;20(2):357-374.
doi: 10.5114/aoms/186191. eCollection 2024.

2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders

Affiliations

2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders

Bogdan Solnica et al. Arch Med Sci. .

Abstract

Lipid disorders are the most common (even 70%) and worst monitored cardiovascular risk factor (only 1/4 of patients in Poland and in CEE countries are on the low-density lipoprotein cholesterol (LDL-C) goal). To improve this, clear and simple diagnostic criteria should be introduced for all components of the lipid profile. These are the updated guidelines of the two main scientific societies in Poland in the area - the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA), which, in comparison to those from 2020, introduce few important changes in recommendations (two main lipid targets, new recommendations on LDL-C measurements, calculations new goals for triglycerides, new recommendations on remnants and small dense LDL) that should help the practitioners to be early with the diagnosis of lipid disorders and in the effective monitoring (after therapy initiation), and in the consequence to avoid the first and recurrent cardiovascular events.

Keywords: guidelines; high-density lipoprotein cholesterol (HDL-C); laboratory diagnostics; lipid disorders; low-density lipoprotein cholesterol; non-HDL-C; triglicerides.

PubMed Disclaimer

Conflict of interest statement

Bogdan Solnica: lecturer: Abbott Laboratories, Argenta, Beckman-Coulter, DiaSorin, Roche Diagnostics, Siemens Healthineers; Jacek Jóźwiak: speaker: Valeant, Servier, Boehringer Ingelheim; consultant Servier, Microlife, Teva, ALAB, Amgen; grants from Valeant; Sławomir Kasperczyk: lecturer/consultant: Mylan, Boehringer Ingelheim, Novartis; Marlena Broncel: Lectures/advisor for Amgen, Novartis, Sanofi, Sandoz; Anna Wolska: Co-author on publications related to Sampson-NIH equations for LDL-C and sdLDL-C; disclaimer: the findings and conclusions in this report are the author and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; Maciej Banach – remuneration for lectures from Adamed, Amgen, Daiichi Sankyo, Exceed Orphan, KRKA, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Pfizer, Sanofi, Teva, Zentiva; participation in advisory panels for Adamed, Amgen, Daiichi Sankyo, Esperion, NewAmsterdam, Novartis, Novo-Nordisk, Sanofi; grants from: Amgen, Daiichi Sankyo, Mylan/ Viatris, Sanofi; other authors reported no conflict of interest.

Figures

Figure 1
Figure 1
Plasma lipoprotein particles size and density with the cholesterol they contain as a marker of their plasma levels
Figure 2
Figure 2
Lipoprotein metabolism ABC A1 – ATP-binding cassette transporter A1, CETP – cholesterol ester transporter protein, EL – endothelial lipase, HL – hepatic lipase, LCAT – lecithin cholesterol acyltransferase, LPL – lipoprotein lipase, PLTP – phospholipid transport protein, TG – triglycerides.
Figure 3
Figure 3
TRL particle size and density VLDL remnants are in the IDL (intermediate density lipoprotein) and VLDL density classes, while chylomicron remnants (CM remnants) fall into the CM, VLDL and IDL density classes.
Figure 4
Figure 4
TRL remnants and atherosclerosis
Figure 5
Figure 5
HDL subpopulations and measurement techniques
Figure 6
Figure 6
Dysfunctional HDL particles: A – HDL modified by myeloperoxidase, B – inflammatory HDL SAA – serum amyloid A, PON-1 – paraoxonase-1, GPx – glutathione peroxidase, RCT – reverse cholesterol transport, ABCA1 – ATP-binding membrane cassette transporter A1.

References

    1. Banach M, Jankowski P, Jóżwiak J, et al. PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for family Physicians 2016. Arch Med Sci 2017; 13: 1-45. - PMC - PubMed
    1. Langlois MR, Nordestgaard BG, Langsted A, et al.; the European Atherosclerosis Society (EAS) and the European federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative . Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med 2020; 58: 496-517. - PubMed
    1. Langlois MR, Chapman MJ, Cobbaert C, et al.; the European Atherosclerosis Society (EAS) and the European federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative . Quantifying Atherogenic Lipoproteins: Current and future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clin Chem 2018; 64: 1006-1033. - PubMed
    1. Mach F, Baigent C, Catapano AL, et al.; The Task force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-88. - PubMed
    1. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021; 17: 1447-547. - PMC - PubMed